Companies › ImmuneOncia Therapeutics
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Danburstotug (IMC-001) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 2 | Extranodal NK/T-cell Lymphoma, Nasal Type; TMB-H; Subjects With Resectable and Localized Gastric Cancer | Feb 2027 |
| IMC-002 | – | Phase 1 | Advanced Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04414163 | Danburstotug (IMC-001) | Phase 2 | Extranodal NK/T-cell Lymphoma, Nasal Type | Oncology | Feb 2027 |
| NCT06365840 | Danburstotug (IMC-001) | Phase 2 | TMB-H | Oncology | Jun 2027 |
| NCT05276310 | IMC-002 | Phase 1 | Advanced Cancer | Oncology | Dec 2027 |
| NCT04196465 | Danburstotug (IMC-001) | Phase 2 | Subjects With Resectable and Localized Gastric Cancer | Oncology | Sep 2028 |
AstraZeneca Pfizer IO Biotech Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan) Shanghai Henlius Biotech
3D Medicines (Sichuan) InxMed (Shanghai) Lantheus Medical Imaging Newish Biotech (Wuxi) Zhejiang Hisun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.